Company Encyclopedia
View More
name
Krystal Biotech
KRYS.US
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc.
1.946 T
KRYS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking19/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE19.66%A
    • Profit Margin53.30%A
    • Gross Margin95.64%A
  • Growth ScoreA
    • Revenue YoY54.51%A
    • Net Profit YoY279.80%A
    • Total Assets YoY26.24%A
    • Net Assets YoY28.45%A
  • Cash ScoreB
    • Cash Flow Margin187.60%C
    • OCF YoY54.51%A
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreA
    • Gearing Ratio8.24%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

    PITTSBURGH, Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Krystal Biotech, Inc. ( the "Company" ) ( NASDAQ: KRYS ) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. Krish S.

    GlobeNewswire·
    US
    KRYS
    +2.07%
    GlobeNewswire·
    US
    KRYS
    +2.07%

    How Investors Are Reacting To Krystal Biotech (KRYS) Surging Revenue and Global VYJUVEK Expansion

    Krystal Biotech reported strong Q3 2025 results, driven by VYJUVEK's success and efficient operations. The company is expanding globally, launching VYJUVEK in Germany, France, and Japan, and forming distribution partnerships. Despite strong results, risks include revenue volatility and product concentration. Krystal's revenue is projected to reach $849.4 million by 2028, with a fair value estimate of $223.00. Community fair value estimates vary widely. Investors should consider the impact of international expansion and operational efficiency on long-term growth.

    Simplywall·
    US
    KRYS
    +2.07%
    Simplywall·
    US
    KRYS
    +2.07%

    Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

    Vertex Pharmaceuticals Inc. (VRTX) stock fell 3.33% to $421.03 on Wednesday, underperforming compared to competitors like AbbVie Inc. and Krystal Biotech Inc. Despite a favorable trading session for the market, VRTX closed 18.98% below its 52-week high of $519.68. The S&P 500 Index rose 0.38% and the Dow Jones Industrial Average rose 0.10%.

    Dow Jones·
    US
    KRYS
    +2.07%
    US
    ABBV
    -0.66%
    Dow Jones·
    US
    KRYS
    +2.07%
    US
    ABBV
    -0.66%

    Envestnet Asset Management Inc. Acquires 2,717 Shares of Krystal Biotech, Inc. $KRYS

    Envestnet Asset Management Inc. increased its stake in Krystal Biotech, Inc. by 21.9% in Q2, purchasing an additional 2,717 shares, now owning 15,116 shares valued at $2,078,000. Other institutional investors also adjusted their holdings. Krystal Biotech's stock opened at $208.25, with a market cap of $6.04 billion. Analysts have given the stock a consensus rating of 'Moderate Buy' with a target price of $228.14.

    Market Beat·
    US
    KRYS
    +2.07%
    Market Beat·
    US
    KRYS
    +2.07%

    How Investors May Respond To Krystal Biotech (KRYS) Surging Net Income and EPS Growth in Q3 2025

    Krystal Biotech reported a significant increase in Q3 2025 net income to $79.37 million from $27.18 million a year ago, with EPS rising to $2.74 from $0.95. This growth reflects improved operational efficiencies and market adoption of key products. The FDA's recent label expansion for VYJUVEK could further boost earnings. However, volatility in patient treatment patterns remains a challenge. Analysts' fair value estimates for the stock vary widely, highlighting the importance of diverse perspectives on its outlook.

    Simplywall·
    US
    KRYS
    +2.07%
    Simplywall·
    US
    KRYS
    +2.07%
    © 2025 Longbridge｜Disclaimer